1. The 2-year progression-free survival was 50.6% in the durvalumab group vs 63.7% in the cetuximab group with HR 1.33...

1. The median progression-free survival was 15.0 months in the inavolisib and 7.3 months in the placebo group, with HR...

1. Progression-free survival had a hazard ratio of 0.38 (extrapancreatic NETs) and 0.23 (pancreatic NETs) for those treated with cabozantinib...

1. The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse...

1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in...

1. Median PFS (5.6 months vs 5.6 months) and median OS (21.4 months vs 18.1 months) were similar in both...

1. The median progression-free survival in the metastasis-directed therapy arm was 10.3 months vs 2.5 months in the control arm...

1. When comparing corticosteroid peak dose for immunosuppression for anti–PD-1 plus anti–CTLA-4–related adverse events, the HR for OS was 1.66...

1. Median overall survival was 41 months in the TKI-only group vs 40 months in the TKI-SRS group, with HR...

1. Co-occurrences could be clustered together into 7 clusters based on the predominant organ system affected; endocrine, cutaneous, respiratory, gastrointestinal,...